SuperworthLivaNova EPS LIVN
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- $3.39
- Latest quarter, Q2 FY26
- $1.93
- +286% on a year earlier
- Fiscal year 2025
- −$4.45
- −490% on the year before
LivaNova's earnings per share was $3.39 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $1.93, up 286% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.45 | −490% |
| FY2024 | $1.14 | +256% |
| FY2023 | $0.32 | n/a |
| FY2022 | −$1.62 | n/a |
| FY2021 | −$2.72 | n/a |
| FY2020 | −$7.17 | n/a |
| FY2019 | −$3.21 | n/a |
| FY2018 | −$3.91 | n/a |
| FY2017 | −$0.54 | n/a |
| FY2016 | −$1.30 | n/a |
| FY2015 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.93 | +286% | $3.39 | |
| Q1 FY26 | $0.40 | n/a | $1.96 | |
| Q4 FY25 | $0.57 | −44% | −$4.45 | |
| Q3 FY25 | $0.49 | −18% | −$4.00 | |
| Q2 FY25 | $0.50 | +67% | −$3.89 | |
| Q1 FY25 | −$6.01 | n/a | −$4.09 | |
| Q4 FY24 | $1.02 | +240% | $1.14 | |
| Q3 FY24 | $0.60 | n/a | $0.42 | |
| Q2 FY24 | $0.30 | +1400% | −$0.32 | |
| Q1 FY24 | −$0.78 | −657% | −$0.60 | |
| Q4 FY23 | $0.30 | +900% | $0.32 | |
| Q3 FY23 | −$0.14 | n/a | $0.05 |
Against its peers
Companies in Medical - Devices nearest LivaNova's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LIVNLivaNova | $3.39 | |
| ITGRInteger | $3.66 | +61% a year |
| TMDXTransMedics | $3.84 | +99% a year |
| CNMDCONMED | $1.85 | −48% a year |
| ZBHZimmer Biomet | $4.11 | +0% a year |
| DXCMDexCom | $2.52 | +76% a year |
| GEHCGE HealthCare Technologies | $4.36 | −11% a year |
| Peer median | $3.75 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on LivaNova
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.